Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $37.00 at JPMorgan Chase & Co.

Maze Therapeutics (NASDAQ:MAZE) had its price objective raised by JPMorgan Chase & Co. from $27.00 to $37.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts have also issued research reports about the stock. Guggenheim boosted their price target on shares of Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a report on Monday, September 15th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Maze Therapeutics in a research report on Thursday, September 18th. BTIG Research increased their target price on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a report on Friday, September 12th. Wedbush assumed coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 target price for the company. Finally, Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $33.83.

Maze Therapeutics Stock Down 6.7%

Shares of NASDAQ MAZE opened at $25.20 on Monday. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $28.37. The business has a fifty day simple moving average of $17.23 and a 200-day simple moving average of $13.27.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Insider Buying and Selling at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Investors Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. TRV GP IV LLC acquired a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $66,874,000. Frazier Life Sciences Management L.P. raised its position in Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares in the last quarter. ARCH Venture Management LLC acquired a new stake in Maze Therapeutics in the first quarter valued at approximately $45,362,000. Matrix Capital Management Company LP bought a new stake in Maze Therapeutics in the first quarter worth approximately $27,373,000. Finally, Alphabet Inc. acquired a new position in shares of Maze Therapeutics during the 1st quarter worth $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.